Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?

Area of Science:

• Immunology
• Molecular Biology
• Biochemistry

Background:

• The thymus gland produces crucial immune-modulating molecules, including thymosins.
• Prothymosin alpha (proTα) is an immunoactive polypeptide derived from thymosin fraction V.
• ProTα exhibits intracellular roles in cell survival and proliferation, and extracellular roles as a biological response modifier.

Purpose of the Study:

• To provide a historical overview of thymosin discovery and isolation, focusing on proTα.
• To present new data on immune-related activities of proTα and its smaller immunostimulatory peptides.
• To propose a model for proTα's mechanism of action for potential clinical applications.

Main Methods:

• Fractionation of thymic extracts to isolate immunoactive polypeptides.
• Identification of the carboxy-terminal decapeptide proTα(100-109) as the main immunoactive region.
• Investigation of signaling pathways, including Toll-like receptor 4 (TLR4) activation by proTα and proTα(100-109).

Main Results:

• ProTα functions intracellularly and extracellularly, with potential as a tumor biomarker and therapeutic agent.
• ProTα and its decapeptide fragment proTα(100-109) activate Toll-like receptor 4.
• ProTα demonstrates pleiotropic adjuvant activity, including anticancer, antiviral, neuroprotective, and cardioprotective effects.

Conclusions:

• ProTα and its fragments possess significant immunomodulatory and adjuvant properties.
• Signaling via TLR4 is a key mechanism for proTα's immune effects.
• ProTα and its derivatives show promise as therapeutic agents for immune deficiencies and as adjuvants in cancer immunotherapy.